TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
In an October 6, 2026, first-person report for Being Patient, Ron Carr recounts three health notifications that changed how he thinks about Alzheimer’s and cardiovascular risk. His account describes learning he has two APOE4 copies, discovering coronary artery plaque on a scan, and reassessing prevention; it is a personal story, not evidence that these tests predict an individual’s future or prevent dementia.
Patient advocate Ron Carr says three health notifications changed how he viewed his risk of Alzheimer’s disease and cardiovascular disease: a genetic report showing two copies of APOE4, a coronary artery scan showing calcified plaque, and a further notification whose details are not included in the supplied excerpt. In a personal report published by Being Patient on October 6, 2026, Carr describes how the results prompted him to reconsider prevention, while stressing through his account that a genetic risk factor is not a diagnosis.
Carr writes that he learned about his two APOE4 copies through a genetic test two years before his article. He initially interpreted the result as a forecast of Alzheimer’s, scrutinizing ordinary lapses in memory and trying successive diets, supplements and exercise routines. He says he later came to understand APOE4 as a risk factor rather than proof he would develop the disease.
A clinician at the University of Southern California then explained to Carr that APOE4 is also involved in lipid transport, according to his account. Carr underwent a coronary artery calcium scan, which he says showed significant calcified plaque, concentrated mostly in the left anterior descending artery. At age 65, he says, he was diagnosed with atherosclerotic cardiovascular disease. Follow-up testing found no evidence of structural heart damage, he reports.
Carr writes that the scan led his clinician to lower his LDL cholesterol and ApoB targets and to prescribe stronger medication. The supplied article excerpt ends as he begins describing a third notification, so its nature and the actions it prompted cannot be established from the material available here.
How Genetic Risk Changed His Prevention
Carr’s account illustrates how a risk result can influence decisions well beyond the condition named on a report. In his case, learning about APOE4 led to a conversation about cholesterol and a scan that identified coronary plaque before, he says, a heart attack or symptoms. That is a description of his experience, not proof that genetic testing or scanning produces the same outcome for others.
The distinction between risk and diagnosis matters for readers considering genetic information. A result can inform a discussion with a clinician, but it does not determine an individual’s future. Carr’s account also shows that receiving unexpected health information can bring anxiety and affect family life, as well as change clinical decisions.
genetic testing for Alzheimer's risk
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
The APOE4 Result and Heart Scan
APOE4 is associated with increased risk of late-onset Alzheimer’s disease, but carrying the variant does not by itself establish that someone has Alzheimer’s. Carr says his first reaction was to treat forgetfulness as evidence of impending illness. Over time, he reframed the result as information about risk rather than a prediction.
He also describes a family history that shaped his approach to heart health: his father had a heart attack at 65. Carr says he had run regularly, changed his diet and eventually took statins, believing his cholesterol was acceptable. The calcium scan changed that understanding by showing plaque despite his feeling healthy. The account does not provide his scan score, laboratory values, medication names or the clinical guidance in full.
Carr refers to a Lancet Commission estimate that up to 45% of dementia cases may be attributable to potentially modifiable risk factors. That is a population-level estimate cited in his article, not a claim that an individual can eliminate their personal risk through lifestyle changes.
“APOE4 is not a diagnosis. It is a risk factor.”
— Ron Carr, in his Being Patient report
Details Missing From the Third Alert
The supplied excerpt does not identify the third health notification, despite the article’s title. It also does not include the full report, so the third result, its timing, any medical interpretation and what Carr did in response remain unknown here. The excerpt provides no independent medical records or clinician comment to verify the specifics of his diagnosis and treatment.
Carr’s story cannot establish how likely APOE4 carriers are to develop Alzheimer’s, whether his scan would have found disease without genetic testing, or whether his treatment will prevent future illness. Those questions require evidence beyond a single person’s account. Readers should not treat his medication or diet changes as recommendations for their own care.
What Readers Can Verify Next
The next step for a fuller account is the complete Being Patient report, which may explain the third notification and Carr’s response. Until those details are available, reporting should not infer what the alert concerned or present it as a confirmed development.
For people weighing genetic testing, cardiovascular scans or changes to treatment, the article supports a narrower takeaway: discuss what a result can and cannot tell you with a qualified health professional. Decisions about testing, medication and prevention depend on individual circumstances and clinical assessment.
Key Questions
What did Carr learn from his genetic test?
He says the report showed two copies of APOE4, a genetic risk factor associated with late-onset Alzheimer’s. That result is not an Alzheimer’s diagnosis.
What did the coronary scan show?
Carr says it showed significant calcified plaque in his coronary arteries, concentrated mostly in the left anterior descending artery. He reports that a clinician diagnosed him with atherosclerotic cardiovascular disease.
What was the third health notification?
The supplied excerpt does not say. Its details, including what the notification concerned, remain unconfirmed in the source material provided.
Does carrying APOE4 mean someone will develop Alzheimer’s?
No. Carr’s account describes APOE4 as a risk factor, not a diagnosis. A personal risk result does not determine an individual outcome; discuss genetic results with a qualified health professional.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
